Clinical trials: Obesity Overweight
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity
Safety and Efficacy of Low Doses of V24343 in Obese Subjects
Randomised, double-blind, parallel group comparison of four dose levels of V24343 and placebo to study the effect of V24343 on blood pressure and weight in obese subjects.
- Trial name
- NCT00734201
- Testing
- V24343
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vernalis (R&D) Ltd
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé
Overweight, Obesity
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
- Trial name
- NCT07767175
- Testing
- NNC0721-8060, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity, Type2 Diabetes Mellitus
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study…
- Trial name
- NCT05762471
- Testing
- GSBR-1290
- Where
- 4 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on: weight loss and waist circumference, blood pressure, cholesterol, glucose other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α…
- Trial name
- NCT00134199
- Testing
- CP-945,598, sibutramine
- Where
- 15 sites in United States
- Volunteers
- 282 people
- Sponsor
- Pfizer
Obesity
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
The purpose of this study is to determine if CP-945,598 is effective in the prevention of weight regain in obese subjects.
- Trial name
- NCT00483171
- Testing
- CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 699 people
- Sponsor
- Pfizer
Obesity
A Study to Evaluate ALN-6222 in Participants With Obesity
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222…
- Trial name
- NCT07624071
- Testing
- ALN-6222
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Alnylam Pharmaceuticals
Overweight and Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity
The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity
- Trial name
- NCT07559136
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women
The aim of the study is to evaluate the effects of a dietary supplement (Obex®) on anthropometric and physiological variables in Spanish women between 35 and 60 years who are overweight or obese.
- Trial name
- NCT01934036
- Testing
- Obex
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Catalysis SL
Morbid Obesity
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
The pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs.
- Trial name
- NCT05486325
- Testing
- Endolumik Gastric Calibration Tube (EGCT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Endolumik, Inc
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
Study of Coffee Mannooligosaccharides for Weight Management
The goal of this study is to establish the role of coffee mannooligosaccharides (MOS), provided in a beverage format, on body weight regulation.
- Trial name
- MOS (NCT00932750)
- Testing
- Coffee mannooligosaccharide, Coffee mannooligosaccharides
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Obesity & Overweight
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity.
- Trial name
- NCT07622810
- Testing
- Bofanglutida, Semaglutide
- Where
- 6 sites in Mexico
- Volunteers
- 352 people
- Sponsor
- Carnot Laboratories
Lack of Satiety
Effects of Soy Protein/Soy Fiber on Measures of Satiety
The purpose of this study is to determine whether ingestion of a bar containing either added soy protein or soy fiber or both, increases subjective and objective measures of satiety compared to a control bar.
- Trial name
- NCT01358318
- Testing
- Satiety
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Solae, LLC
Overweight/ Obesity
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a multicenter, double-blind, randomized, placebo-controlled study conducted in overweight or obese subjects. This study is divided into the first stage and the second stage.
- Trial name
- NCT04904913
- Testing
- IBI362
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Healthy, Obesity
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product [formulation A]) and in a vial (test product [formulation B2]) in male and female trial participants…
- Trial name
- NCT07768813
- Testing
- Survodutide formulation A, Survodutide formulation B2
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin
- Trial name
- NCT06064006
- Testing
- NNC0487-0111
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novo Nordisk A/S
Healthy, Liver Diseases
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts.
- Conditions
- Healthy, Liver Diseases, Obesity
- Trial name
- NCT05296733
- Testing
- BI 456906
- Where
- 13 sites in United States, Germany and 4 more
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
This study examines whether a gradual increase of dose improves the gastrointestinal tolerability (nausea and vomiting) of PF05212389
- Trial name
- NCT01472848
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.